Progress of nuclide targeted α-particle therapy for blood tumors
10.3760/cma.j.cn321828-20230721-00008
- VernacularTitle:血液肿瘤α粒子核素治疗进展
- Author:
Shanqi HUO
1
;
Jin WANG
;
Bei ZHANG
;
Kai CAO
;
Shaohua SUN
;
Cheng CHEN
;
Chunyan LIU
;
Shicang SU
Author Information
1. 长江大学附属荆州医院核医学科，荆州 434020
- Keywords:
Hematologic neoplasms;
Radiotherapy;
Alpha particles;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2024;44(9):564-568
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of blood tumors is getting higher and higher. In addition to traditional chemoradiotherapy, in recent years, with the development of nuclear medicine technology and nuclide, nuclide therapy is playing an increasingly important role in the treatment of blood tumors. At present, the main research on the treatment of blood tumors focuses on acute myeloid leukemia (AML), but progress has also been made in other blood tumors. 213Bi and 225Ac-labeled monoclonal antibodies have achieved good results in blood tumors. 225Ac has overcome the short half-life of 213Bi and the problems of transportation and preservation. However, there are still many problems to be solved in the clinical use of α particles. This article reviews the progress of α-particle therapy in blood system, in order to provide a broader idea for the treatment of blood tumors.
